RENEURON

 

RENEURON (RENE.L, LSE, LSE:RENE)

RENE Share PerformanceMore

52 week high6.500 15/07/15
52 week low2.750 08/08/14
52 week change 2.210 (69.07%)
4 week volume51,389,684 10/07/15

Media for (RENE)

Presenter: Michael Hunt, CEO
04/02/2015

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Publication of Circular and Notice of GM

RNS Number: 4785U ReNeuron Group plc 29 July 2015 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE REPUBLI...

FTSE surges on Greece hopes as financials, retail soar

FTSE and European bourses flew higher on hopes Greece and its austerity-minded creditors will finally ink a bailout agre...

Should You Invest In Vodafone Group plc, ReNeuron Group Plc Or Zotefoams plc?

Today I am looking at three FTSE headline grabbers in Friday business. Vodafone Group With a much-awaited deal to sol...

FTSE flies on financials, airlines as Greece hopes soar

FTSE and European indices vaulted higher as traders dared hope a resolution to the chronic Greece-debt soap might be in ...

ReNeuron retains its confidence despite reported loss

ReNeuron Group plc ("ReNeuron" or the "Company"), a leading UK-based stem cell company, has announced that for th...

FTSE soars on Greece hopes as IHG takes pole

FTSE and European indices raced higher as investors increasingly hope a bailout solution will be reached between Greece ...

ReNeuron's news

ReNeuron Group has raised a total of 68.4m gross via a conditional placing that will enable the Company to build on the c...

Placing to Raise £68.4 million

RNS Number: 7052S ReNeuron Group plc 10 July 2015 THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE REPUBLIC...

Fundamental DataMore

EPS-0.5
Dividend yield0 %

Equity Research (RENE)

edison investment research
ReNeuron Group plc
23/04/2015
ReNeuron presented two-year follow-up data from the PISCES study in disabled stroke patients, which confirm the potential for long-term benefits from treatment with its CTX neural stem cells....
edison investment research
ReNeuron Group plc
28/11/2014
ReNeuron is facing a potentially transformational year in 2015, with key clinical data and relocation to a new cell manufacturing/research facility. Its allogeneic, CTX neural stem cell product is...
edison investment research
ReNeuron Group plc
29/09/2014
ReNeuron operates off solid fundamentals as it seeks to advance its novel stem cell technology. Last year’s £25.3m fundraise coupled with a £7.8m grant from the Welsh government to build a new...

Users' HoldingsMore

Users who hold RENEURON also hold..
LLOYDS GRP.13%
BARCLAYS12%
GLAXOSMITHKLINE12%
BP12%
ROYAL BANK SCOT10%

Codes & Symbols

ISINGB00B0DZML60
SymbolsRENE, LSE:RENE, RENE.L, RENE:LN, LON:RENE, XLON:RENE